We are proud to announce that our portfolio company Thermosome has reported encouraging results from its ongoing Phase 1 clinical trial evaluating its lead compound THE001 for the treatment of soft tissue sarcomas. Despite the early stage of development and small number of participants, signs of meaningful clinical activity have already emerged. It is particularly noteworthy that one participant with previously unresectable disease underwent surgery, indicating no vital tumor cells remaining in the target lesion. These results build a strong foundation for advancing to Phase 2 trials and expanding the study.
THE001 utilizes a heat-triggered release mechanism designed to achieve higher local drug concentrations and improved tumor response, even in heavily pre-treated patients. Across both tested dose levels, THE001 in combination with regional hyperthermia demonstrated a favorable safety profile, with no dose-limiting toxicities or high-grade treatment-related adverse events observed. These findings underscore the promise of this innovative approach for patients with advanced soft tissue sarcoma.
We look forward to supporting Thermosome as they advance into Phase 2 trials and continue their mission to transform cancer therapy for patients with limited treatment options.
More information in the press release under the following link
More about Thermosome
